Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 80

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 80
---
 ability
to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct
our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit
our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses
on terms unfavorable to us.

Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions, including a change of control.

After this offering, our
directors, officers, holders of more than 5% of our outstanding shares and their respective affiliates will beneficially own shares representing
approximately 59.2% of our outstanding Ordinary Shares, assuming no exercise of the Representative’s option to purchase additional
shares and additional warrants without giving effect to any shares that certain of these holders may make through our directed share
program or otherwise. As a result, these shareholders, if they act together, will be able to influence our management and affairs and
all matters requiring shareholder approval, including the election of directors and approval of significant corporate transactions. This
concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market
price of our Ordinary Shares.

The JOBS Act, allows us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market price of our ADSs or our Ordinary Shares.

For so long as we remain an
“emerging growth company” as defined in the JOBS Act, we intend to take advantage of certain exemptions from various requirements
that are applicable to public companies that are not “emerging growth companies” including:

| ● | the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting; |

| ● | Section 107 of the JOBS Act, which provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This means that an “emerging growth